Compare Novartis AG (NVS) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Exxon Mobil Corporation — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Exxon Mobil Corporation trades at $159.26 (market cap $634.34B). The key difference: Exxon Mobil Corporation is far larger — about 2.1× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| NVS | XOM | |
|---|---|---|
Market Cap | $298.18B | $634.34B |
Sector | Health | Energy |
52-Week High | $168.62 | $171.52 |
52-Week Low | $119.31 | $106.13 |
Enterprise Value | $339.50B | $673.57B |
Dividend Yield | 3.02% | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
ExxonMobil (XOM) trades at $159.80, up 4.49% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q1 2026 but missing in Q2, while revenue and net income have trended lower since 2022. The company maintains robust cash flow from operations and a solid balance sheet with low debt levels, supporting consistent dividends.
Outlook remains positive due to high oil price forecasts and Permian Basin growth, but risks include declining profitability margins and geopolitical volatility. The stock offers value near the consensus price target of $163.71, with institutional sentiment leaning bullish amid energy sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
